IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS WHO UNDERGO MATCHED UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

被引：0
|
作者：
Sayyed, A. [1 ]
Altareb, M. [1 ]
Chen, C. [1 ]
Gerbitz, A. [1 ,2 ]
Kim, D. [1 ,2 ]
Lam, W. [1 ,2 ]
Law, A. [1 ,2 ]
Lipton, J. [1 ,2 ]
Michelis, F. [1 ,2 ]
Novitzky-Basso, I. [1 ,2 ]
Viswabandya, A. [1 ,2 ]
Kumar, R. [1 ,2 ]
Mattsson, J. [1 ,2 ]
Pasic, I. [1 ,2 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Hans Messner Allogene Transplant Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P139
引用
收藏
页数：1
相关论文
共 50 条
  • [31] IN VIVO T-CELL DEPLETION (TCD) DOES NOT IMPROVE RATES OF GRAFT-VERSUS-HOST DISEASE (GVHD) AND TRANSPLANTATION OUTCOMES IN PATIENTS UNDERGOING PERIPHERAL BLOOD ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (AHCT)
    Kanate, A. S.
    Osman, S.
    Cumpston, A.
    Hobbs, G.
    Leadmon, S.
    Bunner, P.
    Gibson, L.
    Tse, W.
    Abraham, J.
    Remick, S.
    Craig, M.
    Hamadani, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S309 - S310
  • [32] Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation
    Mishra, Asmita
    Anasetti, Claudio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S49 - S52
  • [33] OUTCOMES OF MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Parikh, S. H.
    Martin, P. L.
    Prasad, V. K.
    Szabolcs, P.
    Ciocci, G.
    Driscoll, T. A.
    Kurtzberg, J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S248 - S249
  • [34] IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
    Mohty, Razan
    Vanegas, Yenny Moreno
    Heckman, Michael G.
    Alkhateeb, Hassan B.
    Hochwald, Alexander P.
    Hogan, William J.
    Kharfan-Dabaja, Mohamed A.
    Ketterling, Rhett P.
    Khera, Nandita
    Litzow, Mark R.
    Mangaonkar, Abhishek A.
    Murthy, Hemant S.
    Palmer, Jeanne M.
    Shah, Mithun, V
    Sproat, Lisa Z.
    Viswanatha, David S.
    Foran, James M.
    BLOOD, 2022, 140 : 4863 - 4864
  • [35] Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
    Choi, Eun-Ji
    Lee, Je-Hwan
    Lee, Jung-Hee
    Park, Han-Seung
    Ko, Sun-Hye
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Kyoo-Hyung
    BLOOD RESEARCH, 2018, 53 (04) : 288 - 293
  • [36] Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
    Choi, Eun-Ji
    Lee, Je-Hwan
    Lee, Jung-Hee
    Park, Han-Seung
    Ko, Sun-Hye
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Kyoo-Hyung
    BONE MARROW TRANSPLANTATION, 2018, 53 : 668 - 669
  • [37] Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome
    Modi, D.
    Deol, A.
    Kim, S.
    Ayash, L.
    Alavi, A.
    Ventimiglia, M.
    Bhutani, D.
    Ratanatharathorn, V.
    Uberti, J. P.
    BONE MARROW TRANSPLANTATION, 2017, 52 (11) : 1530 - 1536
  • [38] Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome
    D Modi
    A Deol
    S Kim
    L Ayash
    A Alavi
    M Ventimiglia
    D Bhutani
    V Ratanatharathorn
    J P Uberti
    Bone Marrow Transplantation, 2017, 52 : 1530 - 1536
  • [39] Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndrome (MDS): A Single Center Experience
    Abello, Virginina
    Villamizar, Licet
    Pedraza, Enrique
    Rosales, Carmen
    Rosales, Manuel
    Figueroa, Javier
    Cordoba, Iris
    Esguerra, Herman
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S211 - S211
  • [40] OUTCOMES OF PATIENTS WITH AML WHO UNDERGO SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT OR DONOR LYMPHOCYTE INFUSION
    Ku, G. H.
    Lane, T. A.
    Castro, J. E.
    Mulroney, C. M.
    Ball, E. D.
    Curtin, P. T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S247 - S247
12345